View ValuationAedifica/SA 향후 성장Future 기준 점검 2/6Aedifica/SA (는) 각각 연간 0.02% 및 21% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 22.8% 만큼 쇠퇴할 것으로 예상됩니다. 자기자본이익률은 3년 후 6.9% 로 예상됩니다.핵심 정보0.02%이익 성장률-22.81%EPS 성장률Health Care REITs 이익 성장4.8%매출 성장률21.0%향후 자기자본이익률6.91%애널리스트 커버리지Good마지막 업데이트01 Jun 2026최근 향후 성장 업데이트공시 • Oct 30+ 3 more updatesAedifica NV/SA Revises Earnings Guidance for the Year 2025Aedifica NV/SA revised earnings guidance for the year 2025. For the year, the company expected EPRA Earnings for 2025 are increased to approx. €5.10/share (previously €5.01/share), excluding the transaction costs related to the exchange offer.공시 • Feb 21+ 1 more updateAedifica NV/SA Provides Earnings Guidance for the Year 2025Aedifica NV/SA provided earnings guidance for the year 2025. For the year, the company expected EPRA Earnings for 2025 are estimated at €238 million, or €5.01 per share.공시 • Oct 30Aedifica NV/SA Increases Earnings Guidance for the Year 2024Aedifica NV/SA increased earnings guidance for the year 2024. For the year, the company Estimated EPRA Earnings per share for the full 2024 financial year are increased to at least €4.90/share (previously €4.85/share).공시 • Jul 31Aedifica NV/SA Provides Earnings Guidance for the Year 2024Aedifica NV/SA provided earnings guidance for the year 2024. For the year, the company EPRA Earnings for 2024 are estimated at €231 million (previously €223 million). EPRA Earnings per share are estimated €4.85/share (previously €4.70/share).공시 • Nov 01Aedifica NV/SA Revises Earnings Guidance for the Year 2023Aedifica NV/SA revised earnings guidance for the year 2023. Estimated EPRA Earnings per share for the full 2023 financial year are increased to at least €4.95/share (previously €4.85/share), including a €0.21/share one-off EPRA result following the obtention of the FBI regime for the Dutch subsidiaries.공시 • Aug 04Aedifica NV/SA Revises Earnings Guidance for the Year 2023Aedifica NV/SA revised earnings guidance for the year 2023. Estimated EPRA Earnings for the 2023 financial year slightly increased to €212 million (previously €209 million) and EPRA Earnings per share are estimated at €4.85/share (previously €4.78/share).모든 업데이트 보기Recent updatesReported Earnings • May 21First quarter 2026 earnings released: EPS: €7.68 (vs €1.32 in 1Q 2025)First quarter 2026 results: EPS: €7.68 (up from €1.32 in 1Q 2025). Revenue: €117.8m (up 23% from 1Q 2025). Net income: €432.3m (up €369.5m from 1Q 2025). Revenue is forecast to stay flat during the next 3 years compared to a 3.1% growth forecast for the Health Care REITs industry in Europe. Over the last 3 years on average, earnings per share has increased by 42% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.Board Change • May 20High number of new directorsThere are 7 new directors who have joined the board in the last 3 years. Independent Director Xavier de Walque was the last director to join the board, commencing their role in 2026. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.공시 • Mar 05Aedifica NV/SA, Annual General Meeting, May 12, 2026Aedifica NV/SA, Annual General Meeting, May 12, 2026.공시 • Feb 13Aedifica Nv/Sa Proposes DividendThe Aedifica NV/SA proposed dividend of €4.00 per share (gross), to be distributed in May 2026, is confirmed.공시 • Oct 30+ 3 more updatesAedifica NV/SA Revises Earnings Guidance for the Year 2025Aedifica NV/SA revised earnings guidance for the year 2025. For the year, the company expected EPRA Earnings for 2025 are increased to approx. €5.10/share (previously €5.01/share), excluding the transaction costs related to the exchange offer.공시 • Oct 14Aedifica NV/SA to Report Fiscal Year 2025 Results on Feb 13, 2026Aedifica NV/SA announced that they will report fiscal year 2025 results at 7:30 AM, Central European Standard Time on Feb 13, 2026공시 • Feb 27Aedifica NV/SA to Report Nine Months, 2025 Results on Oct 28, 2025Aedifica NV/SA announced that they will report nine months, 2025 results on Oct 28, 2025공시 • Feb 21+ 1 more updateAedifica NV/SA Provides Earnings Guidance for the Year 2025Aedifica NV/SA provided earnings guidance for the year 2025. For the year, the company expected EPRA Earnings for 2025 are estimated at €238 million, or €5.01 per share.공시 • Nov 22Aedifica NV/SA to Report Q1, 2025 Results on Apr 29, 2025Aedifica NV/SA announced that they will report Q1, 2025 results at 5:40 PM, Central European Standard Time on Apr 29, 2025공시 • Oct 30Aedifica NV/SA Increases Earnings Guidance for the Year 2024Aedifica NV/SA increased earnings guidance for the year 2024. For the year, the company Estimated EPRA Earnings per share for the full 2024 financial year are increased to at least €4.90/share (previously €4.85/share).공시 • Oct 23Aedifica NV/SA to Report Fiscal Year 2024 Results on Feb 19, 2025Aedifica NV/SA announced that they will report fiscal year 2024 results at 7:30 AM, Central European Standard Time on Feb 19, 2025공시 • Sep 10Aedifica NV/SA (ENXTBR:AED) acquired Furze Field Manor, Copperfield Court & Rownhams Manor Trading Care Homes in UK of Oyster Care Homes Limited.Aedifica NV/SA (ENXTBR:AED) acquired Furze Field Manor, Copperfield Court & Rownhams Manor Trading Care Homes in UK of Oyster Care Homes Limited on September 6, 2024. In a separate transaction, Aedifica NV/SA signed an agreement to acquire Somer Valley House in Midsomer Norton from Oyster Care Homes Limited. The transactions had a combined deal value of £61.5 million. Aedifica NV/SA (ENXTBR:AED) completed the acquisition of Furze Field Manor, Copperfield Court & Rownhams Manor Trading Care Homes in UK of Oyster Care Homes Limited on September 6, 2024.공시 • Jul 31Aedifica NV/SA Provides Earnings Guidance for the Year 2024Aedifica NV/SA provided earnings guidance for the year 2024. For the year, the company EPRA Earnings for 2024 are estimated at €231 million (previously €223 million). EPRA Earnings per share are estimated €4.85/share (previously €4.70/share).공시 • May 03+ 2 more updatesAedifica NV/SA, Annual General Meeting, May 13, 2025Aedifica NV/SA, Annual General Meeting, May 13, 2025.Reported Earnings • Apr 06Full year 2023 earnings released: EPS: €0.56 (vs €8.71 in FY 2022)Full year 2023 results: EPS: €0.56 (down from €8.71 in FY 2022). Revenue: €321.1m (up 15% from FY 2022). Net income: €24.5m (down 93% from FY 2022). Profit margin: 7.6% (down from 119% in FY 2022). Revenue is forecast to grow 4.6% p.a. on average during the next 3 years, compared to a 2.0% growth forecast for the Health Care REITs industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 18% per year whereas the company’s share price has fallen by 17% per year.Declared Dividend • Apr 04Final dividend of €1.60 announcedShareholders will receive a dividend of €1.60. Ex-date: 16th May 2024 Payment date: 22nd May 2024 Dividend yield will be 5.7%, which is lower than the industry average of 7.4%.Declared Dividend • Mar 01Final dividend of €1.60 announcedShareholders will receive a dividend of €1.60. Ex-date: 16th May 2024 Payment date: 22nd May 2024 Dividend yield will be 6.1%, which is lower than the industry average of 7.4%.공시 • Nov 01Aedifica NV/SA to Report Nine Months, 2024 Results on Oct 30, 2024Aedifica NV/SA announced that they will report nine months, 2024 results on Oct 30, 2024Reported Earnings • Nov 01Third quarter 2023 earnings released: EPS: €0.69 (vs €3.49 in 3Q 2022)Third quarter 2023 results: EPS: €0.69 (down from €3.49 in 3Q 2022). Revenue: €81.4m (up 15% from 3Q 2022). Net income: €32.8m (down 76% from 3Q 2022). Profit margin: 40% (down from 196% in 3Q 2022). Revenue is forecast to grow 6.3% p.a. on average during the next 3 years, compared to a 3.1% growth forecast for the Health Care REITs industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has fallen by 19% per year, which means it is performing significantly worse than earnings.공시 • Nov 01Aedifica NV/SA Revises Earnings Guidance for the Year 2023Aedifica NV/SA revised earnings guidance for the year 2023. Estimated EPRA Earnings per share for the full 2023 financial year are increased to at least €4.95/share (previously €4.85/share), including a €0.21/share one-off EPRA result following the obtention of the FBI regime for the Dutch subsidiaries.공시 • Sep 26+ 3 more updatesAedifica NV/SA to Report Fiscal Year 2023 Results on Feb 21, 2024Aedifica NV/SA announced that they will report fiscal year 2023 results on Feb 21, 2024공시 • Aug 04Aedifica NV/SA Revises Earnings Guidance for the Year 2023Aedifica NV/SA revised earnings guidance for the year 2023. Estimated EPRA Earnings for the 2023 financial year slightly increased to €212 million (previously €209 million) and EPRA Earnings per share are estimated at €4.85/share (previously €4.78/share).Valuation Update With 7 Day Price Move • Jun 28Investor sentiment deteriorates as stock falls 19%After last week's 19% share price decline to €52.53, the stock trades at a forward P/E ratio of 11x. Average forward P/E is 21x in the Health Care REITs industry globally. Total loss to shareholders of 37% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €69.21 per share.Buying Opportunity • Jun 22Now 22% undervalued after recent price dropOver the last 90 days, the stock is down 21%. The fair value is estimated to be €73.71, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 21% over the last 3 years. Earnings per share has grown by 26%. For the next 3 years, revenue is forecast to grow by 7.5% per annum. Earnings is also forecast to grow by 22% per annum over the same time period.공시 • Jun 02An unknown buyer entered into an agreement to acquire portfolio of 10 buildings in Finland from Aedifica NV/SA (ENXTBR:AED) for €25.6 million.An unknown buyer entered into an agreement to acquire portfolio of 10 buildings in Finland from Aedifica NV/SA (ENXTBR:AED) for €25.6 million on June 1, 2023.The transaction is expected to be completed by the end of June 2023.Reported Earnings • May 11First quarter 2023 earnings released: EPS: €0.40 (vs €3.23 in 1Q 2022)First quarter 2023 results: EPS: €0.40 (down from €3.23 in 1Q 2022). Revenue: €78.6m (up 17% from 1Q 2022). Net income: €16.1m (down 86% from 1Q 2022). Profit margin: 21% (down from 174% in 1Q 2022). Revenue is forecast to grow 6.6% p.a. on average during the next 3 years, compared to a 5.2% growth forecast for the Health Care REITs industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings.Upcoming Dividend • May 06Upcoming dividend of €1.60 per share at 4.9% yieldEligible shareholders must have bought the stock before 12 May 2023. Payment date: 16 May 2023. Trailing yield: 4.9%. Lower than top quartile of British dividend payers (5.8%). Lower than average of industry peers (6.5%).Reported Earnings • Apr 10Full year 2022 earnings released: EPS: €8.71 (vs €8.10 in FY 2021)Full year 2022 results: EPS: €8.71 (up from €8.10 in FY 2021). Revenue: €279.2m (up 15% from FY 2021). Net income: €331.8m (up 18% from FY 2021). Net asset value (NAV) per share: €82.37 (up 12% from FY 2021). The current share price is 13% lower than NAV per share. Revenue is forecast to grow 7.7% p.a. on average during the next 3 years, compared to a 5.2% growth forecast for the Health Care REITs industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.Reported Earnings • Feb 18Full year 2022 earnings released: EPS: €8.71 (vs €8.10 in FY 2021)Full year 2022 results: EPS: €8.71 (up from €8.10 in FY 2021). Revenue: €279.2m (up 15% from FY 2021). Net income: €331.8m (up 18% from FY 2021). Revenue is forecast to grow 8.6% p.a. on average during the next 3 years, compared to a 5.3% growth forecast for the REITs industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings.공시 • Feb 16+ 1 more updateAedifica SA Proposes Earnings Guidance for the Year 2023Aedifica SA proposed earnings guidance for the year 2023. EPRA Earnings for 2023 are estimated at €200 million, or €5.03/share.Board Change • Nov 16High number of new directorsThere are 6 new directors who have joined the board in the last 3 years. COO & Executive Director Raoul Thomassen was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.공시 • Nov 09+ 2 more updatesAedifica SA to Report Q1, 2023 Results on May 10, 2023Aedifica SA announced that they will report Q1, 2023 results on May 10, 2023Board Change • Oct 20High number of new directorsThere are 6 new directors who have joined the board in the last 3 years. COO & Executive Director Raoul Thomassen was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.공시 • Oct 01+ 1 more updateAedifica SA to Report Fiscal Year 2022 Final Results on Mar 30, 2023Aedifica SA announced that they will report fiscal year 2022 final results on Mar 30, 2023Board Change • Sep 08High number of new directorsThere are 6 new directors who have joined the board in the last 3 years. COO & Executive Director Raoul Thomassen was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.Board Change • Aug 19High number of new directorsThere are 6 new directors who have joined the board in the last 3 years. COO & Executive Director Raoul Thomassen was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Aug 06Second quarter 2022 earnings released: EPS: €3.34 (vs €2.03 in 2Q 2021)Second quarter 2022 results: EPS: €3.34 (up from €2.03 in 2Q 2021). Revenue: €67.3m (up 17% from 2Q 2021). Net income: €121.9m (up 79% from 2Q 2021). Over the next year, revenue is forecast to grow 11%, compared to a 6.5% growth forecast for the industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth.Board Change • Jul 22High number of new directorsThere are 6 new directors who have joined the board in the last 3 years. COO & Executive Director Raoul Thomassen was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.Board Change • Jun 30High number of new directorsThere are 6 new directors who have joined the board in the last 3 years. COO & Executive Director Raoul Thomassen was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.Board Change • Jun 02High number of new directorsThere are 6 new directors who have joined the board in the last 3 years. COO & Executive Director Raoul Thomassen was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.Board Change • May 18High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Independent Director Henrike Waldburg was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.Upcoming Dividend • May 06Upcoming dividend of €1.58 per shareEligible shareholders must have bought the stock before 13 May 2022. Payment date: 17 May 2022. Trailing yield: 3.4%. Lower than top quartile of British dividend payers (4.7%). In line with average of industry peers (3.1%).Reported Earnings • Apr 03Full year 2021 earnings released: EPS: €8.10 (vs €4.35 in FY 2020)Full year 2021 results: EPS: €8.10 (up from €4.35 in FY 2020). Revenue: €242.7m (up 36% from FY 2020). Net income: €281.8m (up 144% from FY 2020). Over the next year, revenue is forecast to grow 14% while the reits industry in the United Kingdom is not expected to grow. Over the last 3 years on average, earnings per share has increased by 8% per year whereas the company’s share price has increased by 9% per year.Buying Opportunity • Mar 05Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 12%. The fair value is estimated to be €128, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 26% per annum over the last 3 years. Earnings per share has grown by 8.4% per annum over the last 3 years.Reported Earnings • Nov 13Third quarter 2021 earnings released: EPS €1.61 (vs €0.70 in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: €59.1m (up 26% from 3Q 2020). Net income: €58.2m (up 226% from 3Q 2020). Profit margin: 98% (up from 38% in 3Q 2020). Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has increased by 16% per year, which means it is tracking significantly ahead of earnings growth.Reported Earnings • Aug 12Second quarter 2021 earnings released: EPS €2.04 (vs €0.70 in 2Q 2020)Second quarter 2021 results: Revenue: €54.9m (up 17% from 2Q 2020). Net income: €68.1m (up 282% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has increased by 16% per year, which means it is tracking significantly ahead of earnings growth.Reported Earnings • May 13First quarter 2021 earnings released: EPS €1.35 (vs €0.70 in 1Q 2020)The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: €54.4m (up 16% from 1Q 2020). Net income: €44.7m (up 151% from 1Q 2020). Profit margin: 82% (up from 38% in 1Q 2020). Over the last 3 years on average, earnings per share has increased by 7% per year whereas the company’s share price has increased by 10% per year.Upcoming Dividend • May 07Upcoming dividend of €0.48 per shareEligible shareholders must have bought the stock before 14 May 2021. Payment date: 18 May 2021. Trailing yield: 3.0%. Lower than top quartile of British dividend payers (4.1%). In line with average of industry peers (3.0%).Is New 90 Day High Low • Feb 20New 90-day high: €104The company is up 5.0% from its price of €98.90 on 20 November 2020. The British market is up 6.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the REITs industry, which is up 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €96.96 per share.Is New 90 Day High Low • Jan 28New 90-day high: €101The company is up 16% from its price of €86.50 on 30 October 2020. The British market is up 18% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the REITs industry, which is up 14% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €101 per share.이익 및 매출 성장 예측BATS-CHIXE:AEDB - 애널리스트 향후 추정치 및 과거 재무 데이터 (EUR Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/2028779649604N/A412/31/2027695626584N/A612/31/2026657729-5,737N/A53/31/2026391614N/AN/AN/A12/31/2025369244318318N/A9/30/2025367228N/AN/AN/A6/30/2025361176291292N/A3/31/2025358192N/AN/AN/A12/31/2024347205248248N/A9/30/2024341106N/AN/AN/A6/30/2024334110233234N/A3/31/202432784N/AN/AN/A12/31/202332125229230N/A9/30/202331243N/AN/AN/A6/30/2023301150245246N/A3/31/2023290231N/AN/AN/A12/31/2022279332218219N/A9/30/2022273489N/AN/AN/A6/30/2022265408171171N/A3/31/2022254354N/AN/AN/A12/31/2021243282198198N/A9/30/2021216221N/AN/AN/A6/30/2021198193N/AN/AN/A3/31/2021188150N/AN/AN/A12/31/2020179115119121N/A6/30/2020169105111112N/A3/31/2020157129104106N/A12/31/2019146154N/A99N/A9/30/2019134139N/A94N/A6/30/2019122123N/A89N/A3/31/201911199N/A82N/A12/31/201810074N/A74N/A9/30/20189773N/A80N/A6/30/20189472N/A85N/A3/31/20189272N/A82N/A12/31/20178973N/A79N/A9/30/20178568N/A74N/A6/30/20178263N/A69N/A3/31/20177654N/A63N/A12/31/20167144N/A56N/A9/30/20166642N/A53N/A6/30/20166240N/A50N/A3/31/20166044N/A47N/A12/31/20155847N/A43N/A9/30/20155546N/A40N/A6/30/20155245N/A37N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: AEDB 의 연간 예상 수익 증가율(0.02%)이 saving rate(3.4%) 미만입니다.수익 vs 시장: AEDB 의 연간 수익(0.02%)이 UK 시장(11.5%)보다 느리게 성장할 것으로 예상됩니다.고성장 수익: AEDB 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.수익 대 시장: AEDB 의 수익(연간 21%)이 UK 시장(연간 4.5%)보다 빠르게 성장할 것으로 예상됩니다.고성장 매출: AEDB 의 수익(연간 21%)은 연간 20%보다 빠르게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: AEDB의 자본 수익률은 3년 후 6.9%로 낮을 것으로 예상됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YReal-estate 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/06/09 10:26종가2026/06/09 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Aedifica NV/SA는 20명의 분석가가 다루고 있습니다. 이 중 6명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Celine HuynhBarclaysKai KloseBerenbergValerie Jacob GueziBernstein17명의 분석가 더 보기
공시 • Oct 30+ 3 more updatesAedifica NV/SA Revises Earnings Guidance for the Year 2025Aedifica NV/SA revised earnings guidance for the year 2025. For the year, the company expected EPRA Earnings for 2025 are increased to approx. €5.10/share (previously €5.01/share), excluding the transaction costs related to the exchange offer.
공시 • Feb 21+ 1 more updateAedifica NV/SA Provides Earnings Guidance for the Year 2025Aedifica NV/SA provided earnings guidance for the year 2025. For the year, the company expected EPRA Earnings for 2025 are estimated at €238 million, or €5.01 per share.
공시 • Oct 30Aedifica NV/SA Increases Earnings Guidance for the Year 2024Aedifica NV/SA increased earnings guidance for the year 2024. For the year, the company Estimated EPRA Earnings per share for the full 2024 financial year are increased to at least €4.90/share (previously €4.85/share).
공시 • Jul 31Aedifica NV/SA Provides Earnings Guidance for the Year 2024Aedifica NV/SA provided earnings guidance for the year 2024. For the year, the company EPRA Earnings for 2024 are estimated at €231 million (previously €223 million). EPRA Earnings per share are estimated €4.85/share (previously €4.70/share).
공시 • Nov 01Aedifica NV/SA Revises Earnings Guidance for the Year 2023Aedifica NV/SA revised earnings guidance for the year 2023. Estimated EPRA Earnings per share for the full 2023 financial year are increased to at least €4.95/share (previously €4.85/share), including a €0.21/share one-off EPRA result following the obtention of the FBI regime for the Dutch subsidiaries.
공시 • Aug 04Aedifica NV/SA Revises Earnings Guidance for the Year 2023Aedifica NV/SA revised earnings guidance for the year 2023. Estimated EPRA Earnings for the 2023 financial year slightly increased to €212 million (previously €209 million) and EPRA Earnings per share are estimated at €4.85/share (previously €4.78/share).
Reported Earnings • May 21First quarter 2026 earnings released: EPS: €7.68 (vs €1.32 in 1Q 2025)First quarter 2026 results: EPS: €7.68 (up from €1.32 in 1Q 2025). Revenue: €117.8m (up 23% from 1Q 2025). Net income: €432.3m (up €369.5m from 1Q 2025). Revenue is forecast to stay flat during the next 3 years compared to a 3.1% growth forecast for the Health Care REITs industry in Europe. Over the last 3 years on average, earnings per share has increased by 42% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.
Board Change • May 20High number of new directorsThere are 7 new directors who have joined the board in the last 3 years. Independent Director Xavier de Walque was the last director to join the board, commencing their role in 2026. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
공시 • Mar 05Aedifica NV/SA, Annual General Meeting, May 12, 2026Aedifica NV/SA, Annual General Meeting, May 12, 2026.
공시 • Feb 13Aedifica Nv/Sa Proposes DividendThe Aedifica NV/SA proposed dividend of €4.00 per share (gross), to be distributed in May 2026, is confirmed.
공시 • Oct 30+ 3 more updatesAedifica NV/SA Revises Earnings Guidance for the Year 2025Aedifica NV/SA revised earnings guidance for the year 2025. For the year, the company expected EPRA Earnings for 2025 are increased to approx. €5.10/share (previously €5.01/share), excluding the transaction costs related to the exchange offer.
공시 • Oct 14Aedifica NV/SA to Report Fiscal Year 2025 Results on Feb 13, 2026Aedifica NV/SA announced that they will report fiscal year 2025 results at 7:30 AM, Central European Standard Time on Feb 13, 2026
공시 • Feb 27Aedifica NV/SA to Report Nine Months, 2025 Results on Oct 28, 2025Aedifica NV/SA announced that they will report nine months, 2025 results on Oct 28, 2025
공시 • Feb 21+ 1 more updateAedifica NV/SA Provides Earnings Guidance for the Year 2025Aedifica NV/SA provided earnings guidance for the year 2025. For the year, the company expected EPRA Earnings for 2025 are estimated at €238 million, or €5.01 per share.
공시 • Nov 22Aedifica NV/SA to Report Q1, 2025 Results on Apr 29, 2025Aedifica NV/SA announced that they will report Q1, 2025 results at 5:40 PM, Central European Standard Time on Apr 29, 2025
공시 • Oct 30Aedifica NV/SA Increases Earnings Guidance for the Year 2024Aedifica NV/SA increased earnings guidance for the year 2024. For the year, the company Estimated EPRA Earnings per share for the full 2024 financial year are increased to at least €4.90/share (previously €4.85/share).
공시 • Oct 23Aedifica NV/SA to Report Fiscal Year 2024 Results on Feb 19, 2025Aedifica NV/SA announced that they will report fiscal year 2024 results at 7:30 AM, Central European Standard Time on Feb 19, 2025
공시 • Sep 10Aedifica NV/SA (ENXTBR:AED) acquired Furze Field Manor, Copperfield Court & Rownhams Manor Trading Care Homes in UK of Oyster Care Homes Limited.Aedifica NV/SA (ENXTBR:AED) acquired Furze Field Manor, Copperfield Court & Rownhams Manor Trading Care Homes in UK of Oyster Care Homes Limited on September 6, 2024. In a separate transaction, Aedifica NV/SA signed an agreement to acquire Somer Valley House in Midsomer Norton from Oyster Care Homes Limited. The transactions had a combined deal value of £61.5 million. Aedifica NV/SA (ENXTBR:AED) completed the acquisition of Furze Field Manor, Copperfield Court & Rownhams Manor Trading Care Homes in UK of Oyster Care Homes Limited on September 6, 2024.
공시 • Jul 31Aedifica NV/SA Provides Earnings Guidance for the Year 2024Aedifica NV/SA provided earnings guidance for the year 2024. For the year, the company EPRA Earnings for 2024 are estimated at €231 million (previously €223 million). EPRA Earnings per share are estimated €4.85/share (previously €4.70/share).
공시 • May 03+ 2 more updatesAedifica NV/SA, Annual General Meeting, May 13, 2025Aedifica NV/SA, Annual General Meeting, May 13, 2025.
Reported Earnings • Apr 06Full year 2023 earnings released: EPS: €0.56 (vs €8.71 in FY 2022)Full year 2023 results: EPS: €0.56 (down from €8.71 in FY 2022). Revenue: €321.1m (up 15% from FY 2022). Net income: €24.5m (down 93% from FY 2022). Profit margin: 7.6% (down from 119% in FY 2022). Revenue is forecast to grow 4.6% p.a. on average during the next 3 years, compared to a 2.0% growth forecast for the Health Care REITs industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 18% per year whereas the company’s share price has fallen by 17% per year.
Declared Dividend • Apr 04Final dividend of €1.60 announcedShareholders will receive a dividend of €1.60. Ex-date: 16th May 2024 Payment date: 22nd May 2024 Dividend yield will be 5.7%, which is lower than the industry average of 7.4%.
Declared Dividend • Mar 01Final dividend of €1.60 announcedShareholders will receive a dividend of €1.60. Ex-date: 16th May 2024 Payment date: 22nd May 2024 Dividend yield will be 6.1%, which is lower than the industry average of 7.4%.
공시 • Nov 01Aedifica NV/SA to Report Nine Months, 2024 Results on Oct 30, 2024Aedifica NV/SA announced that they will report nine months, 2024 results on Oct 30, 2024
Reported Earnings • Nov 01Third quarter 2023 earnings released: EPS: €0.69 (vs €3.49 in 3Q 2022)Third quarter 2023 results: EPS: €0.69 (down from €3.49 in 3Q 2022). Revenue: €81.4m (up 15% from 3Q 2022). Net income: €32.8m (down 76% from 3Q 2022). Profit margin: 40% (down from 196% in 3Q 2022). Revenue is forecast to grow 6.3% p.a. on average during the next 3 years, compared to a 3.1% growth forecast for the Health Care REITs industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has fallen by 19% per year, which means it is performing significantly worse than earnings.
공시 • Nov 01Aedifica NV/SA Revises Earnings Guidance for the Year 2023Aedifica NV/SA revised earnings guidance for the year 2023. Estimated EPRA Earnings per share for the full 2023 financial year are increased to at least €4.95/share (previously €4.85/share), including a €0.21/share one-off EPRA result following the obtention of the FBI regime for the Dutch subsidiaries.
공시 • Sep 26+ 3 more updatesAedifica NV/SA to Report Fiscal Year 2023 Results on Feb 21, 2024Aedifica NV/SA announced that they will report fiscal year 2023 results on Feb 21, 2024
공시 • Aug 04Aedifica NV/SA Revises Earnings Guidance for the Year 2023Aedifica NV/SA revised earnings guidance for the year 2023. Estimated EPRA Earnings for the 2023 financial year slightly increased to €212 million (previously €209 million) and EPRA Earnings per share are estimated at €4.85/share (previously €4.78/share).
Valuation Update With 7 Day Price Move • Jun 28Investor sentiment deteriorates as stock falls 19%After last week's 19% share price decline to €52.53, the stock trades at a forward P/E ratio of 11x. Average forward P/E is 21x in the Health Care REITs industry globally. Total loss to shareholders of 37% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €69.21 per share.
Buying Opportunity • Jun 22Now 22% undervalued after recent price dropOver the last 90 days, the stock is down 21%. The fair value is estimated to be €73.71, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 21% over the last 3 years. Earnings per share has grown by 26%. For the next 3 years, revenue is forecast to grow by 7.5% per annum. Earnings is also forecast to grow by 22% per annum over the same time period.
공시 • Jun 02An unknown buyer entered into an agreement to acquire portfolio of 10 buildings in Finland from Aedifica NV/SA (ENXTBR:AED) for €25.6 million.An unknown buyer entered into an agreement to acquire portfolio of 10 buildings in Finland from Aedifica NV/SA (ENXTBR:AED) for €25.6 million on June 1, 2023.The transaction is expected to be completed by the end of June 2023.
Reported Earnings • May 11First quarter 2023 earnings released: EPS: €0.40 (vs €3.23 in 1Q 2022)First quarter 2023 results: EPS: €0.40 (down from €3.23 in 1Q 2022). Revenue: €78.6m (up 17% from 1Q 2022). Net income: €16.1m (down 86% from 1Q 2022). Profit margin: 21% (down from 174% in 1Q 2022). Revenue is forecast to grow 6.6% p.a. on average during the next 3 years, compared to a 5.2% growth forecast for the Health Care REITs industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings.
Upcoming Dividend • May 06Upcoming dividend of €1.60 per share at 4.9% yieldEligible shareholders must have bought the stock before 12 May 2023. Payment date: 16 May 2023. Trailing yield: 4.9%. Lower than top quartile of British dividend payers (5.8%). Lower than average of industry peers (6.5%).
Reported Earnings • Apr 10Full year 2022 earnings released: EPS: €8.71 (vs €8.10 in FY 2021)Full year 2022 results: EPS: €8.71 (up from €8.10 in FY 2021). Revenue: €279.2m (up 15% from FY 2021). Net income: €331.8m (up 18% from FY 2021). Net asset value (NAV) per share: €82.37 (up 12% from FY 2021). The current share price is 13% lower than NAV per share. Revenue is forecast to grow 7.7% p.a. on average during the next 3 years, compared to a 5.2% growth forecast for the Health Care REITs industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.
Reported Earnings • Feb 18Full year 2022 earnings released: EPS: €8.71 (vs €8.10 in FY 2021)Full year 2022 results: EPS: €8.71 (up from €8.10 in FY 2021). Revenue: €279.2m (up 15% from FY 2021). Net income: €331.8m (up 18% from FY 2021). Revenue is forecast to grow 8.6% p.a. on average during the next 3 years, compared to a 5.3% growth forecast for the REITs industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings.
공시 • Feb 16+ 1 more updateAedifica SA Proposes Earnings Guidance for the Year 2023Aedifica SA proposed earnings guidance for the year 2023. EPRA Earnings for 2023 are estimated at €200 million, or €5.03/share.
Board Change • Nov 16High number of new directorsThere are 6 new directors who have joined the board in the last 3 years. COO & Executive Director Raoul Thomassen was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
공시 • Nov 09+ 2 more updatesAedifica SA to Report Q1, 2023 Results on May 10, 2023Aedifica SA announced that they will report Q1, 2023 results on May 10, 2023
Board Change • Oct 20High number of new directorsThere are 6 new directors who have joined the board in the last 3 years. COO & Executive Director Raoul Thomassen was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
공시 • Oct 01+ 1 more updateAedifica SA to Report Fiscal Year 2022 Final Results on Mar 30, 2023Aedifica SA announced that they will report fiscal year 2022 final results on Mar 30, 2023
Board Change • Sep 08High number of new directorsThere are 6 new directors who have joined the board in the last 3 years. COO & Executive Director Raoul Thomassen was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
Board Change • Aug 19High number of new directorsThere are 6 new directors who have joined the board in the last 3 years. COO & Executive Director Raoul Thomassen was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Aug 06Second quarter 2022 earnings released: EPS: €3.34 (vs €2.03 in 2Q 2021)Second quarter 2022 results: EPS: €3.34 (up from €2.03 in 2Q 2021). Revenue: €67.3m (up 17% from 2Q 2021). Net income: €121.9m (up 79% from 2Q 2021). Over the next year, revenue is forecast to grow 11%, compared to a 6.5% growth forecast for the industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth.
Board Change • Jul 22High number of new directorsThere are 6 new directors who have joined the board in the last 3 years. COO & Executive Director Raoul Thomassen was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
Board Change • Jun 30High number of new directorsThere are 6 new directors who have joined the board in the last 3 years. COO & Executive Director Raoul Thomassen was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
Board Change • Jun 02High number of new directorsThere are 6 new directors who have joined the board in the last 3 years. COO & Executive Director Raoul Thomassen was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
Board Change • May 18High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Independent Director Henrike Waldburg was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
Upcoming Dividend • May 06Upcoming dividend of €1.58 per shareEligible shareholders must have bought the stock before 13 May 2022. Payment date: 17 May 2022. Trailing yield: 3.4%. Lower than top quartile of British dividend payers (4.7%). In line with average of industry peers (3.1%).
Reported Earnings • Apr 03Full year 2021 earnings released: EPS: €8.10 (vs €4.35 in FY 2020)Full year 2021 results: EPS: €8.10 (up from €4.35 in FY 2020). Revenue: €242.7m (up 36% from FY 2020). Net income: €281.8m (up 144% from FY 2020). Over the next year, revenue is forecast to grow 14% while the reits industry in the United Kingdom is not expected to grow. Over the last 3 years on average, earnings per share has increased by 8% per year whereas the company’s share price has increased by 9% per year.
Buying Opportunity • Mar 05Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 12%. The fair value is estimated to be €128, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 26% per annum over the last 3 years. Earnings per share has grown by 8.4% per annum over the last 3 years.
Reported Earnings • Nov 13Third quarter 2021 earnings released: EPS €1.61 (vs €0.70 in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: €59.1m (up 26% from 3Q 2020). Net income: €58.2m (up 226% from 3Q 2020). Profit margin: 98% (up from 38% in 3Q 2020). Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has increased by 16% per year, which means it is tracking significantly ahead of earnings growth.
Reported Earnings • Aug 12Second quarter 2021 earnings released: EPS €2.04 (vs €0.70 in 2Q 2020)Second quarter 2021 results: Revenue: €54.9m (up 17% from 2Q 2020). Net income: €68.1m (up 282% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has increased by 16% per year, which means it is tracking significantly ahead of earnings growth.
Reported Earnings • May 13First quarter 2021 earnings released: EPS €1.35 (vs €0.70 in 1Q 2020)The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: €54.4m (up 16% from 1Q 2020). Net income: €44.7m (up 151% from 1Q 2020). Profit margin: 82% (up from 38% in 1Q 2020). Over the last 3 years on average, earnings per share has increased by 7% per year whereas the company’s share price has increased by 10% per year.
Upcoming Dividend • May 07Upcoming dividend of €0.48 per shareEligible shareholders must have bought the stock before 14 May 2021. Payment date: 18 May 2021. Trailing yield: 3.0%. Lower than top quartile of British dividend payers (4.1%). In line with average of industry peers (3.0%).
Is New 90 Day High Low • Feb 20New 90-day high: €104The company is up 5.0% from its price of €98.90 on 20 November 2020. The British market is up 6.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the REITs industry, which is up 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €96.96 per share.
Is New 90 Day High Low • Jan 28New 90-day high: €101The company is up 16% from its price of €86.50 on 30 October 2020. The British market is up 18% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the REITs industry, which is up 14% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €101 per share.